Frustrated with congressional Republican inaction on major pieces of his agenda, President Trump cut deals with Democrats on a short-term increase in the debt ceiling and funding the government. Then to the surprise and consternation of his base, Trump agreed to work on a deal to extend DACA, a Democratic priority. But what does Trump’s new interest in working with Democrats mean for healthcare policy-making? That is not yet clear.
When Maria Fardis, Ph.D., MBA, joined Lion Biotechnologies as CEO, she knew “The word ‘Lion’ didn’t really define us as a company or the advancements we had made with our TIL technology.” So, nine months into her tenure, Fardis and her team began the process of changing the company name to Iovance.
As the cost of developing new medicines continues to rise, more pharmaceutical companies are looking at how artificial intelligence (AI) can help in drug development. But there are some hurdles to overcome before its full potential is reached.
All CEOs of small, publicly traded biotechs are required to wear many hats in the office every day. That’s why having a leader with a diverse background and experience in a variety of functional areas is an asset. Here we look at some of the various areas of expertise that can help create a more diverse C-suite executive.
“The Korean pharmaceutical industry has been accelerating investments in open innovation and focusing on R&D for entry into overseas markets,” says Deborah Chee, president, Korean National Enterprise for Clinical Trials.
Prior to joining Lilly as SVP of clinical and product development, Daniel Skovronsky, M.D., Ph.D. was CEO of Avid Radiopharmaceuticals — a company he founded while still a graduate student. This article is a prequel to the upcoming feature in our November issue that explores how he built a $300 million company.
When I interviewed Axovant Sciences CEO David Hung, one of the questions posed was sparked by our discussion of his experience at Pro-Duct Health and his invention of a microcatheter for early detection of ductal breast cancer in women. As he explained his medical device invention, Hung commented, “I don’t want to be just medicines, or just devices, or anything like that.”
Chief Editor Rob Wright recently conducted an in-person interview with David Hung, formerly of Medivation and current CEO of Axovant Sciences. Though many may credit the FDA’s approval of Medivation’s Xtandi (enzalutamide) as being the primary driver behind Hung’s rise, Wright argues that there are a number of other predictors that should be evaluated when anticipating future success.
Don't miss this free (all-access) sneak peek of our upcoming September feature article on how Brent Saunders built Allergan’s social contract, a document that may likely define his biopharma legacy. “Over time, as people evaluate my leadership in the role, I hope it is not limited to the social contract," he says.
According to KPMG’s 2017 CEO Outlook, more than two-thirds of U.S. life sciences CEOs say their organizations are ready to adopt advanced artificial intelligence (AI) technology, but they acknowledge there are barriers to implementing it.
As concerns about the cost of medicines reach a fever pitch, innovators are looking to leverage a promising advancement to help address the fundamental need for sustainable healthcare in the U.S. — biosimilars.
In the first of this two-part article, Sandoz's Cindy Cao shares lessons learned from working with the FDA and reveals that there is still a lot of room for exploration and innovation in biosimilar development.
Investors are recognizing life sciences real estate as a valuable specialty asset class. In fact, it’s a trend gaining momentum as major real estate investment trusts (REITs) and entrepreneurial investors alike create new homes for life sciences activities.
There is a trend within the pharmaceutical, biopharmaceutical, medical device, and vaccine industries to hire more consultants, leading to a staffing ratio that can be up to 50 percent consultants to staff for small to large capital projects.
Organizations are always looking to optimize the startup process so they can bring products to market quicker — getting potentially lifesaving drugs into the hands of patients is the primary goal — while also reducing each study budget so more products can be pursued to help other patient groups.
Jens Vogel, President & CEO, BI Fremont Inc., can’t help seeing two sides to most everything associated with the development and manufacturing of biologics. For example, he says we are in an era that at the same time can be dubbed “Death of the Blockbuster” and “Return of the Blockbuster.”
FDA Commissioner Scott Gottlieb has taken the wheel at an exciting time, when insights from genomics are starting to come to fruition and promising new therapies based on new technologies are being developed. This article explores some of the policy changes happening now in the regulatory rare disease space — and shifts we expect to see in the future — as the FDA’s leadership team implements these changes at the agency.